Doxorubicin Hydrochloride — 20MG, Solution for injection, box of 1 × 10 mL vial

Doxorubicin Hydrochloride — 20MG, Solution for injection, box of 1 × 10 mL vial

Doxorubicin Hydrochloride is a solution for injection for intravenous use. Doxorubicin is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). 1.1 Adjuvant Breast Cancer DOXOrubicin HCl Injection, USP is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer

• Active ingredient or product type: DOXORUBICIN HYDROCHLORIDE
• Strength/concentration: 20MG
• Dosage form and route: Solution for injection, Intravenous
• Exact package presentation: box of 1 × 10 mL vial
• NDC/item number: 0143-9085-01
• Manufacturer: HIKMA PHARMACEUTICALS USA INC
• Storage/handling: Store refrigerated, 2° to 8°C (36° to 46°F). Protect from light. Discard unused portion.
• Status: Rx only

Important safety information: Radiation-induced toxicity can be increased by the administration of doxorubicin.

Refer to the current product labeling for complete indications, preparation or administration instructions, contraindications, warnings, precautions, and storage requirements.